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ABSTRACT: 
Biotherapeutics is a newer approach towards treatment of diseases using living organisms or 
their products. Probiotics as biotheraputic agents are now the main topic of research that is 
gaining attention of the scientific researchers around the globe. As the definition given by 
FAO/WHO probiotics can be defined as live microorganisms that when administrated in 
adequate amount confers a health benefit on the host. Probiotics when isolated from the 
human Gastro Intestinal Tract become more specific towards treatment of diseases related to 
human beings due to population specificity of the probiotics. These gut micro flora play an 
important role in maintenance of the gut health by conferring certain health benefits and 
preventing the invasion of the disease causing pathogens. Diseases such as salmonellosis, 
inflammatory bowel disease, colon cancer, infectious colitis and infection in urinogenital 
tract are the most common as well as life threatening diseases causing maximum death 
around the world. So treatment of these diseases can be done using biotherapeutic approaches 
including population specific gut microbiota as a replacement of traditional medicines and 
antibiotics. The project work mainly focuses on evaluation of the therapeutic and 
prophylactic activity of human isolates derived from Rourkela region, Odisha against enteric 
pathogens.  
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INTRODUCTION: 
Microbes, the diverse group of organisms have occupied their own distinct niche being 
adapted to the diverse environmental conditions over millions and millions of year. Among 
all the microorganisms, bacteria in itself is a vast group including all beneficial as well as 
harmful bacteria. Disease causing bacteria concerned to human beings has compelled us to 
think bacteria as an organism only with deleterious effect. But certain bacteria also exhibit 
traits that are beneficial to human beings. Probiotics are the ideal example of bacteria that are 
friendly to human society. 
According to UNFAO/WHO probiotics can be defined as the live microorganisms that when 
administered in adequate amounts confer a health benefit on the host [FAO/WHO, 2002]. 
The use of probiotics can be diversified into many different areas such as food, drugs and 
many other dietary supplements. Specific interaction of probiotics with commensal bacteria 
in host gut microbiota implies enhanced impact on host. One organism has to satisfy certain 
criteria to be qualified as a probiotics. These characters can be summarized as follows: 
1. Beneficial effects on the host should be efficient. 
2. Pathogenicity of the probiotics should be zero. 
3. Organisms should be tolerant to the GIT environment (bile and acid tolerant) showing 
viability for a longer period [Marteau, 2006]. 
4. Showing higher rate of adherence to the gastrointestinal epithelial cells 
[Thirabunyanon et al., 2009]. 
Human has sterile gut microbiota during the time of birth which then gets colonized with 
microbes from mother and from the environment and develops into a complex ecosystem 
inhabiting various ranges of microbes [Hooper, 2004]. Most of the microbes of gut ecosystem 
are gram positive and are with low GC content [Qin et al., 2010]. This microbiome 
colonization stimulates the growth of the microbes (approximately 1.5Kg) that are 10 times 
more than that of the host own cells (eukaryotic cells). 400 different species of microbes 
inhabit the gut microbiota [Rolfe, 1997].The functions that are performed by these 
microorganisms can be classified into three major categories that are 
1. Resistance to the colonization of the exogenous microbes (pathogens) and 
uncontrollable growth of the indigenous microbes. 
2.  Enrichment of the innate immune system of host to exhibit quick and infection 
specific response. 
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3. Supplements the host system with nutritional complements such as vitamins, enzymes 
and energy components such as volatile fatty acids [Hayashi et al., 2002]. 
 Life threatening diseases like infectious colitis, colon cancer and inflammatory bowel 
diseases are more common in current arena. Treatment of these diseases needs a newer 
approach and replacement of the traditional medicines and antibiotic use. This newer 
approach involves application of probiotics as a biotherapeutic agent for treatment of several 
diseases. Biotherapeutics can be defined as the use of living organism or their products which 
have beneficial effect on the host. The main focus of using probiotics as therapeutic agent is 
to restore the equilibrium of the gut environment. 
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REVIEW OF LITERATURE: 
 
NEED OF PROBIOTICS: 
Probiotics colonization infers many functions that are beneficial to human beings. Enhancing 
metabolic activity, protection of the host against potential pathogens and nutritional 
supplementation are the main functions that a probiotic performs in the human gastro 
intestinal tract. Nutritional homeostasis is the important phenomena that should be 
maintained to improve the host gastric condition. Microbial imbalance generally known as 
dysbiosis leads to the growth of certain subdominant microorganisms known as pathogens. 
Inflammatory Bowel Disease (IBD) is an example of the dysbiosis mediated gastric disease. 
Probiotics produce certain metabolites that in association with host enzymes such as 
cytochrome P450 metabolize the nutrients in the host body [Nicholson and Wilson, 2003]. 
These metabolized nutrients are then absorbed by the intestinal epithelial cells. Glycans, 
vitamin K, vitamin B, folate and short chain fatty acids (SCFA) are the metabolites produced 
by the probiotic microorganisms [Gill et al., 2006]. These microorganisms also have the 
potential to metabolize substance having carcinogenic effect and other drugs producing either 
beneficial effect or negative impact [Holzapfel et al., 1998]. Probiotic metabolites are needed 
to digest certain indigestible fibers. Probiotics also act as antagonistic agent against certain 
enteric pathogens and prevent certain infectious diseases. Examples of some of these diseases 
are: salmonellosis, shigellosis, inflammatory bowel disease, lactose intolerance, infection of 
colon and dysentery etc. 
The significance of human gut isolates to be used as probiotics are: 
1. Their ability to adhere specifically to the GIT epithelial lining. 
2. Recognized as self by human immune system. 
3. Prevent pathogen from invading into the host cell. 
4. Stimulates immune response in the host on pathogen infection. 
5. Tolerant to acid and bile in the GIT. 
6. Can be isolated easily from the human. 
Probiotics are generally region specific and population specific i.e. the microbiota in the gut 
of individuals in one region varies from that of the individuals of another region. So 
probiotics isolated from individuals of a particular region will specifically work for those 
individuals. Specificity of the probiotics is due to variable environmental conditions, cultural 
differences and fooding habits of the populations of different regions. 
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SALMONELLOSIS:  
Salmonella is a gram negative invasive pathogenic bacterium that having evolved molecular 
machineries that allow Salmonella to get enter into the host cell, survive intracellularly and 
replicate within the host cell. Salmonella can be classified into various serotypes differing 
from each other genetically. This genetic difference between the serotypes leads to the 
development of series of diseases. Salmonellosis is mostly characterized by enteritis. 
Transmission of Salmonella mainly occurs by oral and faecal rout. Salmonella that are 
transmitted from the reptiles cause severe degree of salmonellosis. Salmonellosis may vary 
from gastroenteritis to septicemia. Symptoms that can be observed during gastroenteritis 
include nausea, vomiting, cramping abdominal pain, diarrhoea, headache, fever and severe 
dehydration in case of children and adults. Gastrointestinal symptoms may lead to the 
development of systemic symptoms which are more severe than that of the symptoms of 
gastroenteritis. The symptoms of the enteric disease include fever, anorexia, headache, 
lethargy and constipation. Meningitis and septicaemia are the fatal symptoms of this disease. 
 
ETEROCOCCAL INFECTION: 
Enterococcus faecalis is a gram positive, nonsporulating, facultative anaerobe and 
commensal pathogenic bacterium of GIT causing about 90% of the enterococcal 
infections.Infections that are caused by Enterococcus include endocarditis, sepsis, urinary 
tract infections and surgical wound infections [Jett et al., 1994]. The most common regions of 
the body that are affected by Enterococcus are urinary tract, endocardium, biliary tract, blood 
stream, abdomen, burn wounds, central nervous system, soft tissues and periodontal tissues 
etc. [Gold et al., 1975]. Enterococcal infection includes following steps: 
1. Adherence to host tissue 
2. Invasion and abscess formation 
3. Release of factor for modulation of inflammatory response in the host tissue 
4. production of secreted toxic substances 
 
MECHANISM OF ACTION OF PROBIOTICS: 
Being an only interface between the environment and host GIT plays an important role of 
distinguishing pathogens from the non-pathogenic microbes by means of their mode of 
invasion and presence of organism specific flagella [Borchers et al., 2009]. So colonization of 
the administrated probiotics in the GIT epithelial cells inhibits the growth of the pathogenic 
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bacteria by altering their metabolic activities [O’Toole and Cooney, 2008]. Mechanisms that 
are involved in action of probiotics in human GIT are (figure 1): 
1. Inhibition of pathogens by producing antimicrobial substances 
2. Competition for nutrition 
3. Competitive exclusion 
4. Enhancement of epithelial barrier function 
5. Immunomodulation 
 
Inhibition of pathogens by producing antimicrobial substances: 
Probiotics have the ability of producing potential antimicrobial substances that may range 
from small molecules to the bioactive peptides and other bacteriocins for inhibition of 
pathogenic growth. Bacteriocins are the translated product from the bacterial ribosome and 
can be categorized into 4 classes that are: 
A. Class I- small peptides e.g. nisin 
B. Class II- small heat stable peptides e.g. pediocin 
C. Class III- large heat-labile proteins e.g. helveticin 
D. Class IV- complex bacteriocins [Servin, 2004]  
Listeria monocytogenes is a pathogen which is inhibited by the production of pediocin by 
Pediococcus acidilactici MM33 from human GIT and other 5 strains of Pediococcus spp. by 
the production of several factors such as hydrogen peroxide, lactic acid, exopolysaccharides 
and other proteolytic activities [Yuksekdag and Aslim, 2010]. Lactobacillus reuteri is a 
probiotic strain that produces antibacterial substances named Reuterin against certain enteric 
pathogens [Jones and Versalovic, 2009]. 
 
Competition for nutrition: 
After consumption of nutrient there may be inter specific competition between the probiotic 
species and the pathogens leading to significant growth in the probiotics inhibiting the growth 
of the pathogens. For example Bifidobacterium adolescentis S2-1 is the probiotic strain that 
inhibits the growth of Porphyromonas gingivalis by better utilization of vitamin K which is 
the common growth factor for both the organisms [Hojo et al., 2007]. 
 
Competitive exclusion: 
Probiotics have the ability of eliminating pathogen infections at the infection site by 
preventing their adherence to the carbohydrate moieties of the glycoconjugate receptors at the 
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site of infection on the GIT epithelial cells [Vanderpool et al., 2008]. For example 
colonization of Lactobacillus plantarum 423 in GIT epithelial cells prevents 2 pathogens i.e. 
Clostridium sporogenes and Enterococcus faecalisfrom adhering to the epithelial surface GIT 
[Ramiah et al., 2008]. Bacillus subtilis NC11 in the GIT inhibits the infection caused by 
Salmonella enteritidis. 
 
Enhancement of epithelial barrier function: 
Loss of GIT epithelial barrier function and disruption of tight junction enhances the 
permeability towards pathogens and enterotoxins during pathogenic infections [Guttman et 
al., 2006]. Presence of probiotics enhances the barrier function by inhibiting pathogenic 
bacteria to get attached to the epithelial lining [Reiff and Kelly, 2010]. 
 
Immunomodulation 
Probiotics colonized in the GIT epithelial cells stimulate a cascade of reaction through 
specific interaction between probiotics and cells of the immune system leading to the 
development of innate and acquired immune response [Vanderpool et al., 2008]. For instance 
Lactobacillus plantarum has the ability to induce production of pro inflammatory and anti 
inflammatory substances from mononuclear blood cells. 
 
Figure 1: Different modes of action of probiotics [Thirabunyanon et al., 20009] 
 
RECOMENDED DOSAGE OF PROBIOTICS TO BE ADMINISTRATED DAILY:  
Different clinical trials have been performed to determine the absolute dose of the probiotics 
that can be administrated without any adverse effect on the host body. 106 CFUs are the 
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minimal dose of the commercially available probiotics whereas the dose administration may 
range up to 1012 CFUs [Verna and Lucak, 2010]. The result becomes more significant when 
the dosage of administration increases i.e. 5x109 CFUs is the administration dose for the 
children whereas adults should be administrated with 10x109 CFUs. The dosage of 
administration of different probiotic strains concerned with treatment of different diseases is 
listed in table 1.  
 
Table 1: Recommended dosage of administration of probiotics concerned with different 
diseases in CFUs 
Name of the disease Probiotics used Dose to be 
administrated 
daily in CFUs 
References 
Antibiotic-associated diarrhea 
(AAD) 
LABs 107 to 1011 Verna and Lucak, 2010 
Clostridium difficile colitis 
(CDC) 
Saccharomyces boulardii 2x1010 McFarland et al., 1994 
Irritable Bowel Syndrome (IBS) Bifidobacterium infantis 
35624 
1 x 108 Kligler and Cohrssen, 
2008 
Atopic dermatitis Lactobacillus rhamnosus GG 1 x 1010 (adult) Kligler and Cohrssen, 
2008 
Lactobacillus fermentum 1x109 (children) Kligler and Cohrssen, 
2008 
Ulcerative colitis Escherichia coli Nissle 1x1011 
(induction of 
remission) 
Rembacken et al., 1999 
 
5x1010 
(maintenance of 
remission) 
Kruis et al., 1997 
 
 
Lactobacillus GG 18x109 Zocco et al., 2006 
Bifidobacterium longum 
(along with fructo 
oligosaccharide) 
2x1011 Furrie et al., 2005 
Crohn’s disease Lactobacillus GG 2x109 Schultz et al., 2004 
Escherichia coli Nissle 1x1010 Malchow, 1997 
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OBJECTIVES: 
 
1. Screening for the therapeutic potential of the human isolates against enteric 
pathogens. 
2. Studies on the prophylactic effect of the human isolates against enteric pathogens. 
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MATERIALS AND METHODS: 
 
Chemicals used: 
 
Dulbecco’s phosphate buffer (10X): 
Sodium chloride (NaCl) -80 g/L 
Potassium chloride (KCl) -2 g/L 
Potassium hydrogen phosphate (KH2PO4) -2 g/L 
Sodium phosphate (Na2PO4.2H2O) -14.4 g/L or Na2HPO4 -11 g/L 
Calcium chloride (CaCl2.2H2O) -1.33 g/L (optional) 
Magnesium chloride (MgCl2.6H2O) -1.0 g/L (optional) 
 
Enterococcus agar: 
Enzymatic Digest of Casein -15 g/L 
Enzymatic Digest of Soybean Meal -5 g/L 
Yeast Extract -5 g/L 
Dextrose -2 g/L 
Dipotassium Phosphate -4 g/L 
Sodium Azide -0.4 g/L 
2, 3, 5-Triphenyl Tetrazolium Chloride -0.1 g/L 
Agar -10 g/L 
Final pH: 7.2 ± 0.2 at 25°C 
Hektoen Enteric agar: 
Enzymatic Digest of Animal -16.5 g/L 
Bile Salts Mixture -4.5 g/L 
Lactose -12 g/L  
Sucrose -12 g/L  
Salicin -2 g/L  
Sodium Chloride -5 g/L 
Sodium Thiosulfate -5 g/L 
Ferric Ammonium Citrate -1.5 g/L 
Bromthymol Blue -0.065 g/L 
Acid Fuchsin -0.1 g/L 
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Agar -13.5 g/L 
Final pH: 7.6 ± 0.2 at 25°C 
 
Lactobacillus MRS Agar: (deMan, Rogosa and Sharpe) 
Proteose peptone -10.000 g/L 
Beef extract -10.000 g/L 
Yeast extracts -5.000 g/L 
Dextrose -20.000 g/L 
Polysorbate -80 1.000 g/L 
Ammonium citrate -2.000 g/L 
Sodium acetate -5.000 g/L 
Magnesium sulphate -0.100 g/L 
Manganese sulphate -0.050 g/L 
Dipotassium phosphate -2.000 g/L 
Agar -12.000 g/L 
Final pH (at 25°C) 6.5±0.2 
 
Lactobacillus MRS Broth: (deMan, Rogosa and Sharpe) 
Enzymatic Digest of Animal Tissue -10 g/L 
Beef Extract -10 g/L 
Yeast Extract - 5 g/L 
Dextrose - 20 g/L 
Sodium Acetate - 5 g/L 
Polysorbate 80 -1 g/L 
Potassium Phosphate -2 g/L  
Ammonium Citrate -2 g/L 
Magnesium Sulphate - 0.1 g/L 
Manganese Sulphate -0.05 g/L 
Final pH: 6.5 ± 0.2 at 25°C 
Nutrient Broth (NB): 
Peptic digest of animal tissue -5.000 g/L 
Sodium chloride -5.000 g/L 
Beef extract -1.500 g/L 
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Yeast extracts -1.500 g/L 
Final pH (at 25°C) 7.4±0.2 
 
NB+cys media: 
Glucose -10 g/L 
Calcium chloride (CaCl2) -0.01 g/L 
Magnesium sulphate -0.008 g/L 
Monobasic potassium phosphate (KH2PO4) -0.04 g/L 
Dibasic potassium phosphate (K2HPO4) -0.04 g/L 
Sodium chloride (NaCl) -2.5 g/L 
Yeast extracts -10 g/L 
Peptone -5 g/L 
Cystein HCl -0.5 g/L 
Sodium bicarbonate -0.4 g/L 
Agar powder -20 g/L 
 
Simulated colonic fluid: 
Potassium chloride (KCl) -0.2 g/L 
Sodium chloride (NaCl) -8 g/L 
Potassium hydrogen phosphate (KH2PO4) -0.24 g/L 
Sodium hydrogen phosphate (Na2HPO4) -1.44 g/L 
Proteose peptone -8.3 g/L 
Glucose -3.5 g/L 
pH -7 
 
Soft agar: 
Peptic digest of animal tissue -5.000 g/L 
Sodium chloride -5.000 g/L 
Beef extract -1.500 g/L 
Yeast extracts -1.500 g/L 
Agar -8 g/L 
Final pH (at 25°C) 7.4±0.2 
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Pathogens used: 
Clinical pathogens were gifted by Dr. Satish Sankar, Sri Sakthi Amma Institute of 
Biomedical research, Vellore, Tamil Nadu, India. 
The list of the pathogens is given bellow; 
1. Salmonella typhi 
2. Proteus vulgaris 
3. Proteus mirabilis 
4. Staphylococcus aureus 
5. Escherichia coli 
6. Klebsiella 
7. Morganella morgani 
8. MRSA 
9. Enterococcus faecalis 
 
Human isolates used: 
The human isolates were isolated and screened for various probiotic characteristics from 
healthy volunteers of Rourkela region, Odisha in collaboration with Dr. Sathpathy, ISPAT 
General Hospital, Rourkela. 
The name of the 5 strains of Human isolates is given bellow; 
1. SAE 33 – Pediococcus spp., 
2. SAE 27 – Pediococcus spp., 
3. SAE 25 – Lactobacillus fermentum 
4. SAE 13–Bacillus amyloliquefaciens 
5. SAN 10 – Bacillus subtillis 
 
Culturing the pathogens: 
NB was prepared and autoclaved. Then 30 ml of broth was transferred to each falcon and 
pathogen from the pure culture (from colonies of the plates containing differential media) 
was transferred to the broth. Broth containing pathogen was incubated at 35⁰C for 12 hrs for 
broth to become turbid (growth of pathogen). 
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Culturing the Human isolates: 
Lactobacillus MRS Broth (for aerobic human isolates) and NB+cys broth (for anaerobic 
human isolates) were prepared and autoclaved. 30 ml of broth was poured in each falcon and 
isolate from the pure culture (from the colonies of the MRS agar plates) was inoculated into 
the broth. It was incubated at 35⁰C for 12 hrs for the isolates to grow making the broth turbid. 
 
Agar well diffusion method:  
Muller Hinton agar was prepared. Plates and the agar media were autoclaved and 20 ml of the 
media was poured in each petriplate. After solidification of the media, wells were made on 
the agar plate using 1ml end cut tips. Pathogens were swabbed on the plate using cotton 
swabs and allowed to dry. Human isolate culture was centrifuged at 5000 rpm for 10 minutes 
and 150 µl of cell free supernatant of each isolate was poured in respective labelled wells 
which were then incubated overnight. Diameter of zone of inhibition was measured and 
recorded for further observation. 
 
Soft agar overlay method: (spot test) 
MRS agar was prepared for the aerobic human isolates (SAE33, SAE27, SAE25 and SAE13) 
and NB+cys agar was prepared for anaerobic isolates (SAN 10). Four human isolates (i.e. 
SAE33, SAE27, SAE25 and SAE13) were spotted on each MRS agar plate. SAN10 was 
spotted on petriplates containing NB+cys media. Volume of the human isolates spotted on 
the agar plate was 2.5 µl. The plates were then allowed to dry and kept in 35⁰C for 12 hours 
for growth of the inoculated human isolates. Pathogens were then inoculated in the soft agar 
and poured on the top of the human isolates gently and agar was allowed to solidify. After 
solidification of the soft agar the plates were incubated at 35⁰C for 24 hours and zone of 
inhibitions formed by the antagonistic activity of the human isolates against pathogens were 
observed. 
 
Antibiotic susceptibility test: 
MRS agar media for aerobic human isolates and NB+cys media for anaerobic human isolates 
were prepared and autoclaved. The media were then poured and allowed to solidify. 
Inoculation of the human isolates was done using a cotton swab. After inoculation of the 
human isolates, antibiotic discs were placed above the swabbed human isolates and incubated 
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at 35⁰C for 24 hr. The diameters of zone of inhibitions produced by the antibiotics against the 
human isolates were measured. 
 
Co-culture test: 
NB, Hektoen Enteric agar and MRS agar were prepared and autoclaved. 100 µl of the 
pathogen (Salmonella typhi) was inoculated into 150 ml of the autoclaved nutrient broth and 
100 µl of the pathogen (10ˉ1 dilution) (from the150 ml broth) was inoculated onto the 
Hektoen Enteric plates for initial count of the pathogen. The media with pathogen was 
incubated in 35⁰C and after 12 hrs 100 µl of human isolates (SAE33) was inoculated to the 
pathogen containing media. 100 µl of human isolates (10ˉ1dilution) (from the co-culture 
media i.e. media containing both pathogen and human isolates) was inoculated on to the MRS 
agar for initial CFU of the human isolates. The co-culture media was incubated at 35⁰C and 
CFU of both pathogen and human isolates was determined at an interval of each 12 hrs by 
plating them on to Hektoen Enteric (for pathogen) and MRS (for human isolates) agar and 
counting the colonies. 
 
Aggregation and co-aggregation test: 
Human isolates and pathogen samples were centrifuged at 5000 rpm for 10 minutes. O.D of 
the pathogen and human isolates sample was adjusted to 0.25 (according to Mcfarland 
standard1) at wave length 600 nm .O.D adjustment was done using phosphate buffer saline. 
Different experimental set ups were prepared i.e. human isolates control, pathogen control 
and combination of human isolates and pathogens.  The samples were incubated and allowed 
to co-aggregate with each other (between pathogen and human isolates). O.D of the sample 
was measured at 600nm at 0th, 2nd, 4th and 20th hours in the microplate reader (96 well plates) 
and the data were compiled to observe the % of aggregation between the human isolates and 
pathogens with respect to the control. 
 
Percentage of co-aggregation= [(average of O.D of isolate and pathogen controls - O.D of 
isolate on probiotics) / average of O.D of isolate and pathogen controls] x 100 
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Simulated infected colon experiment: 
 
Calibration of nitrogen sparging time: 
A solution was prepared containing 2.6g of KOH, 3.3g glucose and 3 drops of methylene 
blue. Initially the solution was colourless but when saturated with O2 by sparging the solution 
appeared blue. Then the solution was sparged with N2 until the colour disappeared and no 
blue colour was formed when the tube was shaken. Twice the test tube size twice the head 
space of the experimental test tube was taken means when the size of the test tube will be 
doubled the volume of the solution will also be doubled accordingly. The tube was then 
saturated with O2 and sparged with N2 until no colouration was obtained. The time taken for 
permanent decolouration was noted i.e. 2 minutes. 
 
Inoculation of sample: 
Colonic fluid was prepared and autoclaved. 125 µl of human isolates and pathogens having 
A600=0.25 were added to the simulated colonic model. Inoculation was done using insulin 
syringe. 40 units in the insulin syringe indicate 1 ml. So for taking 0.125 ml sample should be 
taken up to 5 units. 3 experimental setups were prepared i.e. probiotic control, combination of 
human isolates and pathogens and pathogen control. The samples were plated on Hektoene 
Enteric agar (Salmonella), Enterococcos agar (Enterococci) and MRS agar (human isolates) 
at interval of 12 hrs for calculation of CFU. 
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RESULT AND DISCUSSION: 
 
Objective -1: Screening for the therapeutic potential of the human isolates against enteric 
pathogens. 
 
Agar well diffusion method: 
Table 2: Antimicrobial activity of the isolates against enteric pathogens by agar well 
diffusion method 
Isolates Inhibition zone radius in mm for the selective enteric indicative pathogens 
Proteus 
vulgaris 
Proteus 
mirabilis 
Morganella 
morganii 
Salmonella 
typhi 
Klebsiella 
spp. 
Enterococcifaecalis E. 
coli 
        
SAE 13 1.5 2.0 1.5 2.0 2.0 - - 
SAE 33 4.0 3.0 3.0 3.0 1.8 - - 
SAE 25 - - - 2.0 - - - 
SAE 27 - - - 3.0 - - - 
SAN 10 - - - - - 9.0 8.0 
- No activity 
In agar well diffusion method the cell free supernatant of the isolates were taken which was 
then poured in the well made on the agar plate. The supernatant then diffused through the 
agar and zone of inhibitions were observed (table 2). In case of SAE 13 and SAE33, they 
showed zone of inhibition against Proteus vulgaris, Proteus mirabilis, Morganella morgani, 
Salmonella typhi and Klebsiella. SAE 25 and SAE27 showed inhibition zone only against 
Salmonella typhi. In case of SAN 10 zone of inhibition was only observed against 
Enterococci faecalis and E. coli. From the above result it can be concluded that all the 
isolates except SAN 10 show antagonistic activity against Salmonella typhi. As SAE 13 and 
SAE 33 show maximum antagonistic activity, so these isolates has been considered for 
further experiments. Presence of zone of inhibition indicates the presence of certain bioactive 
peptides like bacteriocins, organic acids, hydrogen peroxide that have inhibitory activity 
against pathogens.  
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Soft agar overlay method: 
Table 3: Antimicrobial activity of the isolates against enteric pathogens by spotting and soft 
agar overlay method 
 
- No activity 
In case of the soft agar overlay method concentrated form of metabolites produced by the 
isolates would be made available in the spotted region. This would show a realistic effect 
happening in the colon where the colon epithelial lining would be colonized by the competing 
probiotic bacterial species .In colon epithelial lining these isolates may competitively exclude 
the invasion of pathogens by secreting metabolites which inhibits the growth of pathogens. 
Thus spot test is used to screen the antagonistic potential of the human isolates with respect to 
prophylactic and/or therapeutic potential. In this experiment, 4 isolates i.e. SAE 13, SAE 33, 
SAE 25 and SAE27 showed presence of zones of inhibitions against all the 9 pathogens, 
these are Proteus vulgaris, Proteus mirabilis, Morganella morgani, Salmonella typhi, 
Klebsiella, Enterococci faecalis, E. coli, Staphylococcus aureus and MRSA.SAN 10 showed 
zone of inhibition only against 2 pathogens i.e. Enterococci faecalis and E. coli. Clear zone 
of inhibitions are observed against Morganella morgani, klebsiella and Salmonella typhi. 
From table 3it can be inferred that SAE 33has higher antagonism than that of other isolates. 
So SAE 33 has been taken into consideration for further experiments. Soft agar overlay 
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method showed higher zone of inhibition than the agar well diffusion because of the higher 
concentration of the isolates resulting in higher production and diffusion of the substance that 
shows antagonistic activity. 
Co-culture test: (Antagonistic activity of human isolates in NB spiked with Salmonella 
under aerobic condition) 
 
 
Figure 2: Dynamics in the viable cell count (CFU) of pathogen and human isolates in co-
culture system. 
In co-culture experiment after inoculation of the pathogen (Salmonella typhi) isolate (SAE 
33) was added after 12 hrs. So as shown in the graph (figure 2) plotted between time and log 
of CFU count, Salmonella typhi shows logistic growth in first 12 hrs before the addition of 
the human isolates. After addition of the human isolates the growth of the pathogen was 
inhibited and a plateau was observed even after 24 hrs of incubation. But there was 
observable increase in the CFU of the human isolates after 24 hrs. Plateau in the human 
isolates growth was observed after 72 hrs. From this experiment it can be concluded that in a 
medium containing human isolates and pathogens, growth of human isolates are higher than 
the pathogen which then arrested the growth of Salmonella typhi by producing antimicrobial 
substances. This experiment was conducted in aerobic condition as the human isolates were 
facultative anaerobes the can grow in both aerobic and anaerobic conditions.  
0
1
2
3
4
5
6
7
8
9
10
0 12 24 36 48 60 72 84 96
log CFU pathogen
log CFU SAE33
Dynamics in the viable cell count (CFU) of pathogen and 
probiotic in co-culture system
Time in hour
C
F
U
 c
ou
n
t 
in
 l
og
Addition of isolate SAE 33 
19 
 
Objective -2: Studies on the prophylactic effect of the human isolates against enteric 
pathogens. 
Aggregation and co-aggregation test: 
 
Figure 3: Co-aggregation and self aggregation of human isolate SAE33 on Salmonella typhi 
and Enterococcus faecalis 
 
 
Figure 3 represents 3 experimental set ups i.e. human isolates control (SAE 33), SAE 33 with 
Salmonella typhi and SAE 33 with Enterococcus faecalis. After 2 hrs of incubation co-
aggregation of SAE 33 with Salmonella typhi was least as compared to the co-aggregation of 
SAE 33 with Enterococcus faecalis and self aggregation of SAE 33. But the percentage of 
aggregation of the both the pathogens with the human isolates increased with increase in the 
period of incubation. Highest degree of co-aggregation was observed in case of SAE 33 with 
Enterococcus faecalis. The percentage of self aggregation of SAE 33 remains almost constant 
even after 20 hrs. The co-aggregation of Salmonnella typhi with SAE 33 was also notable. As 
the co-aggregation percentage of Enterococcus faecalis with SAE 33 is highest hence SAE 
33 showed higher antagonism against Enterococcus faecalis than that of Salmonella typhi. 
Result of this reaction can be taken into consideration for inhibition of pathogen by human 
isolates in a simulated colonic environment. 
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Simulated infected colon experiment: 
Antagonistic activity of SAE 33 in SCF against Salmonella: 
 
Figure 4: Reduction in viable cell count (CFU) of Salmonella typhi in presence of human 
isolates SAE 33 with respect to control. 
 
Figure 4 represents 4 experimental setups i.e. Salmonella typhi control, Salmonella typhi with 
SAE 33, human isolates SAE 33 control and human isolates SAE 33 with Salmonella typhi. 
In first 12 hours only human isolates was incubated in the SCF and there was no pathogen, so 
the graph represented only the growth of SAE 33 at 12 hrs. In 24 hrs the human isolates count 
in the tube containing both human isolates and pathogen is higher than that of the human 
isolates control whereas the pathogen count in the tube containing combination of human 
isolates and pathogen is lower than that of the pathogen control. In 36 hrs there is a slight 
decrease in the count of the SAE 33 than that of the control but the pathogen count increases 
than that of the 24 hrs but the count is still less as compared to the control. The count of 
Salmonella typhi in the tube having pathogen and human isolates completely diminished at 
60 hrs whereas growth was still there in the pathogen control. At 72 hrs the human isolates 
were still detected in growing condition in both the human isolates control and also in human 
isolates pathogen combination. From this experiment it can be concluded that in anaerobic 
condition and in an environment similar to human colon the probotic (SAE 33) was showing 
antagonistic activity against Salmonella typhi. As human isolates is active in invitro 
anaerobic colonic environment, hence its effect will be similar in invivo i.e. inside the human 
colon. 
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Antagonistic activity of SAE 33 in SCF against Enterococci: 
 
Figure 5: Reduction in the viable cell count (CFU) of Enterococcus faecalis in the presence 
of human isolates SAE 33 with respect to control.  
In figure 5 the experimental set up involved human isolates control (SAE 33), pathogen 
control (Enterococcus faecalis) and combination of SAE 33 and Enterococcus faecalis. In 
first 12 hrs there was growth of only human isolates. The growth of the Enterococcus faecalis 
decreased gradually as compared to the pathogen control with increase in time which then 
ultimately diminished at 60 hrs but growth was still there in the pathogen control. In 72 hrs 
the count of the pathogen became zero in both the tubes i.e. control and combination of SAE 
33 and Enterococcus faecalis. In case of human isolates in the tube containing combination 
of human isolates and pathogen increased gradually with increase in time. This can be 
inferred from the graph that the survivability of SAE 33 is more than that of Enterococcus 
faecalis.  SAE 33 produced certain agents that acted against Enterococcus faecalis resulting 
in reduced count of the pathogen. 
Both the above experiments represented that SAE 33 was a potential pathogen having 
prophylactic activity in the anaerobic colonic environment. This indicated that after 
colonization in the colon SAE 33 can produce bio chemicals having detrimental effect 
towards invading pathogens. 
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Antibiotic susceptibility test: 
Table 4: Antibiotic susceptibility of isolated human pathogens against certain antibiotics 
Antimicrobial 
agent 
Diameter of zone of inhibition in cm for each isolated strains and 
interpretation 
SAE 13 SAE 33 SAE 25 SAE 27 SAN 10 
Cepodoxime 
(CPD) 10 mcg 
2.02c 1.8c 2.6b 1.8c 2.12b 
Chloramphenicol 
(C) 30 mcg 
5.2b 2.4 b 5.6b 3.4 b 2.1b 
Vancomycin (VA) 
30 mcg 
-a - a - a - a 1.8b 
Streptomycin (S) 
10 mcg 
2.6b 1.2b 3.0b 2.6b 1.4b 
Rifampicin (RIF) 
5 mcg 
3.8b - a 4.4b 3.2b 2.0b 
Levofloxacin (LE) 
5 mcg 
3.6b 1.6c 3.6b 3.0b 1.6c 
Ceftriaxone 
(CTR) 30 mcg 
2.7b 1.4c 4.6b 3.0b 1.6c 
Clindamycin (CD) 
2 mcg 
4.6b - a 5.6b 4.0b 2.8b 
Amoxycillin 
(AMC) 30 mcg 
2.6 b 1.4c 3.6b 3.0b 1.8b 
Amikacin (AK) 30 
mcg 
2.4b 1.2b 2.8b 2.4b 2.0b 
Cefixime (CFM) 5 
mcg 
3.4b 1.6c 3.2b 2.6b 1.2b 
Tertracycline (TE) 
80 mcg 
3.0b 1.6b 4.0b 3.2b 2.2b 
Erythromycin (E) 
15 mcg 
3.0b 3.0b 3.2b 3.1b 2.9b 
Gentamycin 
(GEN) 10 mcg 
1.9c 2.2b 2.2b 2.2b 2.1b 
Penicillin G (P) 
10 units 
3.5b 3.0b 3.3b 3.5b 4.0b 
Interpretation:aresistant, bsensitive,  cIntermediate, according to CLSI 
Vancomycinresistence is intrinsic for Lactobacillus spp., 
The entirehuman isolates show Methicillin resistance. 
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A microorganism to be called as human isolates should show susceptibility to all antibiotics. 
Antibiotic resistance is the intrinsic property of the genomic DNA. If the resistance gene gets 
incorporated into the plasmid DNA it may get transferred to the pathogen through horizontal 
gene transfer inducing antibiotic resistance in the pathogens. Induction of antibiotic resistance 
in pathogen will lead to development of incurable disease in spite of the presence of the 
antibiotics. In table 4all the human isolates strains show susceptibility toward the antibiotics 
used except Vancomycin and Methicillin. So these strains can be used as potential human 
isolates for exhibiting biotherapeutic and prophylactic effect.  
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CONCLUSION: 
The experiments performed above are the standard experiments for evaluation of therapeutic 
as well as prophylactic activity of the human gut isolates against enteric pathogens. The 
human isolates used in this experiment show antagonistic activity against the used strains of 
enteric pathogens. From the co-culture experiment it can be inferred that the presence of 
human isolate SAE 33 inhibits the growth of Salmonella typhi bringing the growth in to a 
plateau which confirms the therapeutic effect of the human isolate. Aggregation co-
aggregation reaction concludes specific binding of the human isolate to the pathogens 
(Salmonella typhi and Enterococcus faecalis). The main evidence of the antagonistic activity 
is obtained by the experiment in simulated infected colonic fluid which concluded that the 
human isolates can induce antagonistic activity in anaerobic, colonic environment. From the 
above mentioned experiments it is obtained that SAE 33 is the most potential human isolate 
having highest antagonistic activity against enteric pathogen. The results of these experiments 
can be referred for future studies. Future studies about these human isolates may include 
encapsulation of these isolated strains for administration into the human body. These human 
isolates can also be incorporated into certain foods such as jelly, yogurt, chocolate and many 
other forms of food material in appropriate dosage and can be taken in normal diet. 
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COLOUR  FIGURES: 
 
 
 
 
 
 
Figure 6: Plate showing antimicrobial activity by 
agar well diffusion method. 
Figure 7: Plates showing antibacterial activity by 
soft agar over lay method. 
A B C 
Figure 8: Plates showing growth of isolates and pathogens in differential media 
A: Growth of Salmonella typhi in Hektoen Enteric agar 
B: Growth of Enterococcus faecalisin in Enterococci confirmatory agar 
C: Growth of isolate in MRS agar 
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Figure 9: Plates showing antibiotic susceptibility test by disc diffusion method. 
Figure 10: Sparging of nitrogen in SCM 
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